Authors

Number of participants at baseline

Gender allocation

Mean age of participants

Group allocation

Intervention duration

Giladi et al., 2021

30

70% male, 30% female

63.8 ± 7.4

19 receiving SoC + ND0612 (270/63 mg daily)

2 weeks

Olanow et al., 2020

38

68% male, 32% female

63.5 ± 9.2

19 receiving SoC + 24-hour infusion of ND0612 (720/90 mg) and 19 receiving SC + 14-hour infusion of ND0612 (536/68 mg + 150/15 mg morning oral dose)

4 weeks

Poewe et al., 2021

214

66.4% male, 33.6% female

64 ± 8.9

90 receiving SoC + 24-hour infusion of ND0612 (720/90 mg) and 124 receiving SoC + 16-hour infusion of ND0612 (720/90 mg)

12 months